DCXR promotes cell proliferation by promoting the activity of aerobic glycolysis in breast cancer

Jin,Yongmei; Zhang,Miao; Tong,Yang; Qiu,Lin; Ye,Ying; Zhao,Bin

doi:10.3892/mmr.2022.12918

DCXR promotes cell proliferation by promoting the activity of aerobic glycolysis in breast cancer

Authors:
- Yongmei Jin
- Miao Zhang
- Yang Tong
- Lin Qiu
- Ying Ye
- Bin Zhao
View Affiliations

Affiliations: Department of General Surgery, The Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai 200137, P.R. China, Central Laboratory, The Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai 200137, P.R. China
Published online on: December 16, 2022 https://doi.org/10.3892/mmr.2022.12918
Article Number: 31
Copyright: © Jin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The function of human dicarbonyl/L‑xylulose reductase (DCXR) in the pathophysiology of breast cancer is yet to be elucidated. The present study aimed to investigate the function of DCXR in glycolysis and the cell cycle of breast cancer cells with respect to cell proliferation. Differential expressed DCXR was identified in The Cancer Genome Atlas (TCGA) database and verified in clinical breast cancer tissue. DCXR silencing and overexpression were induced by RNA interference and lentiviral vectors, respectively. Cell cycle progression, proliferation and glycolytic activity of breast cancer cells were detected by flow cytometry, Cell Counting Kit‑8 assay and chemical methods, respectively. Tumorigenicity was detected using nude mice xenograft models. The expression of DCXR was increased in TCGA breast cancer database and the function of DCXR was enriched in ‘glycolysis’ and ‘cell cycle’. Further analysis using clinical breast cancer samples confirmed upregulation of DCXR. The silencing of DCXR suppressed proliferation and cell cycle progression of breast cancer cells and significantly decreased the capacity for glycolysis, thereby demonstrating the effect of DCXR on the function of breast cancer cells. Similar conclusions were obtained in DCXR overexpressing cells; notably, DCXR overexpression promoted proliferation, cell cycle progression at S phase and glycolysis. 2‑Deoxy‑D‑glucose inhibited the effect of DCXR on the proliferation and cell cycle progression of breast cancer cells. The present study revealed that DCXR regulated breast cancer cell cycle progression and proliferation by increasing glycolysis activity and thus may serve as an oncogene for breast cancer.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Solanki M and Visscher D: Pathology of breast cancer in the last half century. Hum Pathol. 95:137–148. 2020. View Article : Google Scholar : PubMed/NCBI
3	Wang HX and Gires O: Tumor-derived extracellular vesicles in breast cancer: From bench to bedside. Cancer Lett. 460:54–64. 2019. View Article : Google Scholar : PubMed/NCBI
4	Tsang JYS and Tse GM: Molecular classification of breast cancer. Adv Anat Pathol. 27:27–35. 2020. View Article : Google Scholar : PubMed/NCBI
5	Kandel A, Dhillon SK, Prabaharan CB, Hisham SFB, Rajamanickam K, Napper S, Chidambaram SB, Essa MM, Yang J and Sakharkar MK: Identifying kinase targets of PPARgamma in human breast cancer. J Drug Target. 29:660–668. 2021. View Article : Google Scholar : PubMed/NCBI
6	Rossi FA, Steinberg JH, Roitberg EH, Joshi MU, Pandey A, Abba MC, Dufrusine B, Buglioni S, Laurenzi VD, Sala G, et al: USP19 modulates cancer cell migration and invasion and acts as a novel prognostic marker in patients with early breast cancer. Oncogenesis. 10:282021. View Article : Google Scholar : PubMed/NCBI
7	Wang YP and Lei QY: Perspectives of reprogramming breast cancer metabolism. Adv Exp Med Biol. 1026:217–232. 2017. View Article : Google Scholar : PubMed/NCBI
8	Wu Z, Wu J, Zhao Q, Fu S and Jin J: Emerging roles of aerobic glycolysis in breast cancer. Clin Transl Oncol. 22:631–646. 2020. View Article : Google Scholar : PubMed/NCBI
9	Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
10	Vaupel P, Schmidberger H and Mayer A: The Warburg effect: Essential part of metabolic reprogramming and central contributor to cancer progression. Int J Radiat Biol. 95:912–919. 2019. View Article : Google Scholar : PubMed/NCBI
11	Enzo E, Santinon G, Pocaterra A, Aragona M, Bresolin S, Forcato M, Grifoni D, Pession A, Zanconato F, Guzzo G, et al: Aerobic glycolysis tunes YAP/TAZ transcriptional activity. EMBO J. 34:1349–1370. 2015. View Article : Google Scholar : PubMed/NCBI
12	Zhao Y, He J, Yang L, Luo Q and Liu Z: Histone deacetylase-3 modification of MicroRNA-31 promotes cell proliferation and aerobic glycolysis in breast cancer and is predictive of poor prognosis. J Breast Cancer. 21:112–123. 2018. View Article : Google Scholar : PubMed/NCBI
13	Zhang HS, Du GY, Zhang ZG, Zhou Z, Sun HL, Yu XY, Shi YT, Xiong DN, Li H and Huang YH: NRF2 facilitates breast cancer cell growth via HIF1a-mediated metabolic reprogramming. Int J Biochem Cell Biol. 95:85–92. 2018. View Article : Google Scholar : PubMed/NCBI
14	van Weverwijk A, Koundouros N, Iravani M, Ashenden M, Gao Q, Poulogiannis G, Jungwirth U and Isacke CM: Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation. Nat Commun. 10:26982019. View Article : Google Scholar : PubMed/NCBI
15	Perco P, Ju W, Kerschbaum J, Leierer J, Menon R, Zhu C, Kretzler M, Mayer G and Rudnicki M; Nephrotic Syndrome Study Network (NEPTUNE), : Identification of dicarbonyl and L-xylulose reductase as a therapeutic target in human chronic kidney disease. JCI Insight. 4:e1281202019. View Article : Google Scholar : PubMed/NCBI
16	Hu XH, Ding LY, Huang WX, Yang XM, Xie F, Xu M and Yu L: (−)-Epigallocatechin-3-gallate, a potential inhibitor to human dicarbonyl/L-xylulose reductase. J Biochem. 154:167–175. 2013. View Article : Google Scholar : PubMed/NCBI
17	Yang S, Jan YH, Mishin V, Heck DE, Laskin DL and Laskin JD: Diacetyl/l-xylulose reductase mediates chemical redox cycling in lung epithelial cells. Chem Res Toxicol. 30:1406–1418. 2017. View Article : Google Scholar : PubMed/NCBI
18	Ebert B, Kisiela M and Maser E: Human DCXR-another ‘moonlighting protein’ involved in sugar metabolism, carbonyl detoxification, cell adhesion and male fertility? Biol Rev Camb Philos Soc. 90:254–278. 2015. View Article : Google Scholar : PubMed/NCBI
19	Jeffery CJ: Moonlighting proteins: Old proteins learning new tricks. Trends Genet. 19:415–417. 2003. View Article : Google Scholar : PubMed/NCBI
20	Cho-Vega JH, Tsavachidis S, Do KA, Nakagawa J, Medeiros LJ and McDonnell TJ: Dicarbonyl/L-xylulose reductase: A potential biomarker identified by laser-capture microdissection-micro serial analysis of gene expression of human prostate adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 16:2615–2622. 2007. View Article : Google Scholar : PubMed/NCBI
21	Lee SK, Son LT, Choi HJ and Ahnn J: Dicarbonyl/l-xylulose reductase (DCXR): The multifunctional pentosuria enzyme. Int J Biochem Cell Biol. 45:2563–2567. 2013. View Article : Google Scholar : PubMed/NCBI
22	Cho-Vega JH, Vega F, Schwartz MR and Prieto VG: Expression of dicarbonyl/L-xylulose reductase (DCXR) in human skin and melanocytic lesions: morphological studies supporting cell adhesion function of DCXR. J Cutan Pathol. 34:535–542. 2007. View Article : Google Scholar : PubMed/NCBI
23	Hang X, Wu Z, Chu K, Yu G, Peng H, Xin H, Miao X, Wang J and Xu W: Low expression of DCXR protein indicates a poor prognosis for hepatocellular carcinoma patients. Tumour Biol. 37:15079–15085. 2016. View Article : Google Scholar : PubMed/NCBI
24	Xu J, Qin S, Yi Y, Gao H, Liu X, Ma F and Guan M: Delving into the heterogeneity of different breast cancer subtypes and the prognostic models utilizing scRNA-Seq and Bulk RNA-Seq. Int J Mol Sci. 23:99362022. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Shi B, Xue M, Wang Y, Wang Y, Li D, Zhao X and Li X: An improved method for increasing the efficiency of gene transfection and transduction. Int J Physiol Pathophysiol Pharmacol. 10:95–104. 2013.PubMed/NCBI
27	National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals, . Guide for the Care and Use of Laboratory Animals. 8th ed. Washington (DC): National Academies Press (US); 2011, PubMed/NCBI
28	Penault-Llorca F and Radosevic-Robin N: Ki67 assessment in breast cancer: An update. Pathology. 49:166–171. 2017. View Article : Google Scholar : PubMed/NCBI
29	Kim YN, Kim SH, Son LT, Ahnn J and Lee SK: Dicarbonyl/L-xylulose reductase (DCXR) producing xylitol regulates egg retention through osmolality control in Caenorhabditis elegans. Anim Cells Syst (Seoul). 26:223–231. 2013. View Article : Google Scholar : PubMed/NCBI
30	Moskovtsev SI, Jarvi K, Legare C, Sullivan R and Mullen JB: Epididymal P34H protein deficiency in men evaluated for infertility. Fertil Steril. 88:1455–1457. 2007. View Article : Google Scholar : PubMed/NCBI
31	Kim K, Zakharkin SO and Allison DB: Expectations, validity, and reality in gene expression profiling. J Clin Epidemiol. 63:950–959. 2010. View Article : Google Scholar : PubMed/NCBI
32	Icard P, Fournel L, Wu Z, Alifano M and Lincet H: Interconnection between metabolism and cell cycle in cancer. Trends Biochem Sci. 44:490–501. 2019. View Article : Google Scholar : PubMed/NCBI
33	Williams GH and Stoeber K: The cell cycle and cancer. J Pathol. 226:352–364. 2012. View Article : Google Scholar : PubMed/NCBI
34	Salazar-Roa M and Malumbres M: Fueling the cell division cycle. Trends Cell Biol. 27:69–81. 2017. View Article : Google Scholar : PubMed/NCBI
35	Abbaszadeh Z, Cesmeli S and Avci CB: Crucial players in glycolysis: Cancer progress. Gene. 726:1441582020. View Article : Google Scholar : PubMed/NCBI
36	Li L, Liang Y, Kang L, Liu Y, Gao S, Chen S, Li Y, You W, Dong Q, Hong T, et al: Transcriptional regulation of the warburg effect in cancer by SIX1. Cancer Cell. 33:368–385. e3672018. View Article : Google Scholar : PubMed/NCBI
37	Qiao L, Dong C and Ma B: UBE2T promotes proliferation, invasion and glycolysis of breast cancer cells by regualting the PI3K/AKT signaling pathway. J Recept Signal Transduct Res. 42:151–159. 2021. View Article : Google Scholar : PubMed/NCBI